Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Larry Schaaf
Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Related publications
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Phase I Trial of Exemestane in Combination With Metformin and Rosiglitazone in Nondiabetic Obese Postmenopausal Women With Hormone Receptor–positive Metastatic Breast Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
Review of Hormone-Based Treatments in Postmenopausal Patients With Advanced Breast Cancer Focusing on Aromatase Inhibitors and Fulvestrant
ESMO Open
Cancer Research
Oncology
Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Investigational New Drugs
Oncology
Pharmacology
A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Phase II Trial of Dexverapamil and Epirubicin in Patients With Non-Responsive Metastatic Breast Cancer
British Journal of Cancer
Cancer Research
Oncology
Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
Oncologist
Cancer Research
Medicine
Oncology
